INVA Stock Summary and Trading Ideas (Innoviva | NASDAQ:INVA)

Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.

Innoviva trades on the NASDAQ stock market under the symbol INVA.

As of July 1, 2026, INVA stock price declined to $21.90 with 751,153 million shares trading.

INVA has a beta of -0.31, meaning it tends to be less sensitive to market movements. INVA has a correlation of 0.01 to the broad based SPY ETF.

INVA has a market cap of $1.62 billion. This is considered a Small Cap stock.

Last quarter Innoviva reported $98 million in Revenue and $2.22 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $1.79.

In the last 3 years, INVA traded as high as $25.15 and as low as $12.22.

The top ETF exchange traded funds that INVA belongs to (by Net Assets): IJR, VTI, IWM, VB, AVUV.

INVA has underperformed the market in the last year with a price return of +9.0% while the SPY ETF gained +21.9%. INVA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.4% and -3.1%, respectively, while the SPY returned +18.3% and -0.4%, respectively.

INVA support price is $22.27 and resistance is $23.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INVA shares will trade within this expected range on the day.